Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO
82.94xsubscribed

Symbiotec Pharmalab IPO

Pharmaceuticals & Drugs
listed
₹14,070Min. investment

Symbiotec Pharmalab Limited IPO Details

SectorPharmaceuticals & Drugs
Price range₹938 – ₹988
IPO type
Regular
Lot size15 shares
Issue size₹1,757Cr
Red Herring Prospectus
Read
Market cap
₹6,244CrLower than sector avg
RevenueApr 2025 - Mar 2026
₹869.1CrLower than sector avg
Growth rate3Y CAGR
10.16%

Symbiotec Pharmalab IPO Subscription Status

Date
QIB
NII
Retail
Total
24-Aug-26
0.35 times (X)
2.52 times (X)
0.67 times (X)
0.72 times (X)
25-Aug-26
0.36X
7.21X
1.45X
1.57X
26-Aug-26
0.42X
36.43X
5.08X
6.2X
27-Aug-26
142.47X
219.87X
12.76X
82.94X

As on 24-Aug-26, 5:30 PM

Symbiotec Pharmalab IPO Timeline

  1. Pre-apply
    21 Aug 2026
  2. Bid start
    24 Aug 2026
  3. Bid end
    27 Aug 2026
  4. Allotment
    28 Aug 2026
  5. Release of funds
    31 Aug 2026
  6. Demat transfer
    31 Aug 2026
  7. Listing
    1 Sep 2026

About Symbiotec Pharmalab Limited

Symbiotec Pharmalab is a science based pharmaceutical and biotechnology company, driven by research and development with over 30 years of industry experience. It was incorporated in 2002 after founding as a lab-scale steroidal-hormone API manufacturer in 1995.
Over the years, the company has evolved into an industrial-scale, backward-integrated manufacturing platform with capabilities across organic chemistry, biotechnology and complex injectables. As of March 31, 2026, Symbiotec had over 200 customers in more than 40 countries including leading generic and specialty pharmaceutical companies in the United States, Europe and Asia.
The company has global volume market shares at 38.2% and 23.8% for corticosteroid APIs and steroidal-hormone APIs respectively as of FY26. It is also the only Indian and global company with a presence across the top 10 corticosteroid and steroidal-hormone APIs. The company operates as a contract development and manufacturing organization (CDMO), providing services to specialty pharmaceutical and nutraceutical companies globally.
Symbiotec operates through three complementary business verticals: API products, CDMO services and complex injectables. In FY26, API products accounted for 96.07% of revenue from operations at ₹835.01 crore, while complex injectables contributed 3.80% at ₹33.05 crore and CDMO services contributed 0.13% at ₹1.09 crore. The company has a product portfolio of over 60 corticosteroid and steroidal-hormone APIs supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones. These products are used across critical care setups and chronic therapeutic areas.
As of March 31, 2026, Symbiotec operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres (KL). The Rau Facility in Indore houses sterile and non-sterile corticosteroid API manufacturing blocks, with a maximum capacity of 92 MT as of March 31, 2026. The Pithampur Facility comprises dedicated and isolated blocks for steroidal-hormone and corticosteroid API manufacturing, with a maximum fermentation capacity of 300 KL and maximum chemical synthesis capacity of 492.67 MT.
The company has also commissioned two additional manufacturing facilities at Ujjain and Mhow, Madhya Pradesh, taking its aggregate maximum chemical synthesis capacity to 584.67 MT, maximum fermentation capacity to 700 KL and complex injectables capacity to 20 million vials per annum.
As of March 31, 2026, Symbiotec had over 50 domestic customers and over 150 export customers, serving key generic and specialty pharmaceutical companies across North America, Europe and Asia. The company added 101 new distinct customers in FY26. In FY26, 67.04% of revenue from operations was generated from international markets, while 32.96% was generated from domestic markets, including indirect exports to regulated markets. Europe contributed 29.11% of revenue while the United States contributed 13.12% and the rest of the World contributed 24.81% in FY26. As of March 31, 2026, Symbiotec’s R&D staff comprised 156 scientists and engineers. Of these, 117 had master’s degrees and 10 possessed PhDs. The company has spent 3.42%, 4.14% and 2.86% of revenue from operations on R&D in FY26, FY25 and FY24 respectively.
The continued global prevalence of inflammatory and autoimmune diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease and inflammatory bowel disease continue to drive demand for corticosteroid active pharmaceutical ingredients (APIs). Research shows that up to 10% of people in industrialised nations suffer from at least one autoimmune disease. The steroid hormones API market is also boosted by rising demand for reproductive health, metabolic disorder and hormone replacement therapies.
The specialty ingredients market, which includes nutraceuticals, functional foods, industrial enzymes, and agricultural biologicals, was valued at US$ 749.0 billion in 2025, and is projected to expand at a CAGR of 6.7% over the period from 2025 to 2030. The biologics pharmaceutical market is estimated to be worth US$82.3 billion in 2025 and is projected to grow at a CAGR of 11.0% creating opportunities in the company's biotechnology-led efforts.
Symbiotec has invested over ₹798.61 crore in the last three fiscal years to build additional capacities and capabilities in API and complex injectables manufacturing. Capital expenditure was ₹237.31 crore in FY26, ₹392.90 crore in FY25 and ₹176.66 crore in FY24. A slow shift in fermentation API production away from China is being driven by growing geopolitical concerns, supply chain vulnerabilities and tightening environmental regulations. Against this backdrop, Symbiotec has observed an increase in requests for proposals from global pharmaceutical companies. The company expects this trend to support further expansion of its market share, particularly in the United States and European Union markets, supported by its regulatory track record.
Now, Symbiotec Pharmalab is launching its initial public offering (IPO), which consists of a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore only. The total issue size of the IPO is ₹1,757 crore. Its shares will be listed on the NSE and BSE.

How to apply for Symbiotec Pharmalab IPO?

If you are interested in this investment opportunity but unsure how to apply for Symbiotec Pharmalab IPO, here are the steps that you need to follow.
When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for Symbiotec Pharmalab IPO on Upstox:
  • Log in to your Upstox account, using your six-digit PIN
  • After logging in, click on ‘Discover’
  • On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
  • Under the Invest in IPO section, look for the ‘Symbiotec Pharmalab IPO’ tab and click on it
  • Now fill in all the required information, like ‘bid price’ and ‘lot size’
  • Confirm and click on ‘Apply’
  • Accept the mandate on your UPI app

Symbiotec Pharmalab Limited IPO Analysis

IPO REVIEW

Symbiotec Pharmalab IPO | Analysis Video

Should you apply?

Watch our analysts break down the Symbiotec Pharmalab Limited IPO — business model, financials, valuation and key risks — to help you decide whether to apply. The video covers the IPO price band, important dates, and what the subscription numbers mean for retail investors.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Strength and Weakness

Global leadership in some APIs

The company holds global leadership positions in molecules such as Hydrocortisone, Testosterone and Methylprednisolone, with market shares of 80.1%, 76.4% and 76.0%, respectively, in FY26, representing over 50% market share of supply by volume in each of these molecules.

Long-lasting customer relationship

69.49% of revenue from operations at ₹604.01 crore in FY26 contributed by the customers having more than 7 years of relationship with the company. The company added 101 new distinct customers in FY26, 96 in FY25 and 89 in FY24.

Multi scaled, vertically integrated manufacturing platform

As of March 31, 2026, Symbiotec operated two industrial-scale API manufacturing facilities and had commissioned two additional manufacturing facilities, taking aggregate maximum chemical synthesis capacity to 584.67 MT, fermentation capacity to 700 KL and complex injectables capacity to 20 million vials. The company is among the few players in India possessing multi-scale fermentation capabilities capable of producing both high volume and low volume fermentation based products.

Continuous investment in R&D

As of 31 March 2026, Symbiotec had three dedicated R&D centers and R&D activities were organised across organic chemistry, biotechnology and complex injectables platforms. R&D expenditure was ₹29.70 crore, or 3.42% of revenue, in FY26, ₹31.14 crore, or 4.14% of revenue, in FY25 and ₹20.51 crore, or 2.86% of revenue, in FY24.

Strong financial metrics

Return on Capital Employed (ROCE) adjusted for capital expenditure not yet commissioned was at 30.43%, 27.71% and 24.59% in FY26, FY25 and FY24 respectively. Net cash flow from operating activities were ₹174.59 crore in FY26, ₹47.26 crore in FY25 and ₹187.50 crore in FY24.

Objectives of Symbiotec Pharmalab Limited IPO

Repayment of borrowings
75.00%
The company plans to use ₹112.50 crore to repay or prepay its outstanding borrowings.
General corporate purposes
25.00%
Part of the IPO proceeds will be used for general corporate purposes and issue expenses

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹869.1Cr10.16%₹109.9Cr₹6,244Cr51.730.33
This sector (avg.)₹1,331.47Cr0%₹193.4Cr₹10,914.84Cr60.870.43
₹52,578.44Cr---₹10,980.1Cr₹3,82,765.9Cr36.980.03
₹9,360Cr---₹2,191Cr₹1,60,635Cr64.600
₹11,516.09Cr---₹1,911.25Cr₹1,34,051.5Cr62.640.42

*Revenue for financial year 2025-26. Lower P/E and D/E ratios are generally preferred.

Symbiotec Pharmalab IPO Contact Details

Company NameSymbiotec Pharmalab Limited

How to apply for Symbiotec Pharmalab IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Symbiotec Pharmalab Limited IPO FAQs

Investors can apply for the Symbiotec Pharmalab IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Symbiotec Pharmalab IPO is 1757 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Symbiotec Pharmalab IPO will be open between 2026-08-24 and 2026-08-27.
Symbiotec Pharmalab IPO allotment date is 2026-08-31. For Symbiotec Pharmalab IPO allotment status check, you can visit the website of the registrar of the IPO.
For Symbiotec Pharmalab IPO, the IPO registrar is MUFG Intime India Private Limited. You can check Symbiotec Pharmalab IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Symbiotec Pharmalab IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Symbiotec Pharmalab IPO lot size is 15 and minimum order quantity is 15.
Symbiotec Pharmalab IPO has set the price band for its IPO at 988 per equity share with a face value of 2.